Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 13, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $49.00 to $18,216,528.97.

Highlighted Stocks Traded by Insiders:

American Equity Investment Life (AEL) - FREE Research Report

Noble David J, who is Executive Chairman at American Equity Investment Life, sold 50,000 shares at $28.47 on March 13, 2015. Following this transaction, the Executive Chairman owned 1.5 million shares meaning that the stake was reduced by 3.21% with the 50,000-share transaction.

The shares most recently traded at $28.98, up $0.51, or 1.75% since the insider transaction. Historical insider transactions for American Equity Investment Life go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 11,000
  • 24-Week # shares sold: 20,900

The average volume for American Equity Investment Life has been 439,000 shares per day over the past 30 days. American Equity Investment Life has a market cap of $2.2 billion and is part of the financial sector and insurance industry. Shares are down 0.92% year-to-date as of the close of trading on Friday.

American Equity Investment Life Holding Company, through its subsidiaries, operates in the insurance business in 50 states and the District of Columbia. It underwrites fixed annuities, including fixed index annuities and fixed rate annuities, as well as single premium immediate annuities. The stock currently has a dividend yield of 0.69%. The company has a P/E ratio of 18.3. Currently, there is 1 analyst who rates American Equity Investment Life a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AEL - FREE

TheStreet Quant Ratings rates American Equity Investment Life as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full American Equity Investment Life Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BorgWarner (BWA) - FREE Research Report

Cuneo Dennis C, who is Director at BorgWarner, sold 1,000 shares at $58.99 on March 13, 2015. Following this transaction, the Director owned 18,878 shares meaning that the stake was reduced by 5.03% with the 1,000-share transaction.

The shares most recently traded at $59.87, up $0.88, or 1.46% since the insider transaction. Historical insider transactions for BorgWarner go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 20,000

The average volume for BorgWarner has been 2.0 million shares per day over the past 30 days. BorgWarner has a market cap of $13.6 billion and is part of the consumer goods sector and automotive industry. Shares are up 7.01% year-to-date as of the close of trading on Friday.

BorgWarner Inc. manufactures and sells engineered automotive systems and components primarily for powertrain applications worldwide. The stock currently has a dividend yield of 0.87%. The company has a P/E ratio of 21.0. Currently, there are 11 analysts who rate BorgWarner a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BWA - FREE

TheStreet Quant Ratings rates BorgWarner as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full BorgWarner Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merrimack Pharmaceuticals (MACK) - FREE Research Report

Porter Michael E, who is Director at Merrimack Pharmaceuticals, bought 5,000 shares at $11.33 on March 13, 2015. Following this transaction, the Director owned 643,164 shares meaning that the stake was boosted by 0.78% with the 5,000-share transaction.

The shares most recently traded at $11.92, up $0.59, or 4.95% since the insider transaction. Historical insider transactions for Merrimack Pharmaceuticals go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 25,000
  • 24-Week # shares bought: 89,909

The average volume for Merrimack Pharmaceuticals has been 1.6 million shares per day over the past 30 days. Merrimack Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 4.34% year-to-date as of the close of trading on Friday.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Currently, there are 5 analysts who rate Merrimack Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MACK - FREE

TheStreet Quant Ratings rates Merrimack Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Merrimack Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null